We have previously demonstrated that IL-2 based immunotherapy, in combination with CD40 agonist, results in synergistic anti-tumor effects which are CD8+ T-cell dependent but not antigen restricted [3], [9] and (Fig. 1). Here, CD8A is linked to neoplasm.